A PHASE II, DOSE-RANGING STUDY WITH CD-NP, A CHIMERIC NATRIURETIC PEPTIDE, IN ACUTE DECOMPENSATED HEART FAILURE PATIENTS WITH RENAL COMPROMISE  by Lieu, Hsiao Dee et al.
 BEST POSTERS AWARDS
E2029
JACC April 5, 2011
Volume 57, Issue 14
A PHASE II, DOSE-RANGING STUDY WITH CD-NP, A CHIMERIC NATRIURETIC PEPTIDE, IN ACUTE 
DECOMPENSATED HEART FAILURE PATIENTS WITH RENAL COMPROMISE
ACC Poster Contributions
Ernest N. Morial Convention Center, Hall F
Sunday, April 03, 2011, 10:00 a.m.-4:45 p.m.
Session Title: ACC.11 Best Poster Award Competition
Abstract Category: 21. Myocardial Function/Heart Failure—Clinical Pharmacological Treatment
Session-Poster Board Number:  1182-256
Authors: Hsiao Dee Lieu, James Young, Uri Elkayam, Amos Katz, Harald Darius, Sidney Goldstein, Barry Massie, Lisa Costello-Boerrigter, John 
Burnett, Cleveland Clinic, Cleveland, OH, Nile Therapeutics, Inc, San Mateo, CA
Background: CD-NP, a chimeric natriuretic peptide, with veno-arterial vasodilation may simultaneously unload the heart and kidney in acute 
decompensated failure (ADHF) patients. This dose-ranging study investigated the safety and tolerability of CD-NP in ADHF patients (pts).
Methods: ADHF pts with renal compromise, treated with at least one dose of furosemide, were randomized to either active CD-NP or placebo. 
Inclusion criteria were symptomatic ADHF with NT-pro-BNP level >= 1400 pg/mL, systolic blood pressure (SBP) >=105-180 mmHg, and renal 
compromise with creatinine (Cr) clearance of 30-80 mL/min. CD-NP was infused for at least 48 hours at 1.25, 2.5, 3.75, or 5 ng/kg/min and 
placebo. Serial measurements of blood pressure and renal function were performed.
Results: Baseline characteristics shown in table below. There appeared to be a dose-dependent mean maximum SBP reduction compared to 
placebo. The 5 ng/kg/min dose of CD-NP was aborted due to clinically-relevant blood pressure reduction. Serum Cr level in the 1.25, and 2.5 groups 
improved relatively to the placebo cohort by the end of infusion. Plasma cystatin-C level at 1.25, 2.5, and 3.75 doses of CD-NP showed relative 
improvement compared to placebo by the end of infusion period.
Conclusions: CD-NP appeared to be well tolerated. Dose-dependent mean maximum SBP reduction observed. CD-NP at 1.25 and 2.5 ng/kg/min 
appeared to preserve renal function relative to placebo as measured by renal biomarkers.
Placebo (n=16)
1.25 ng/kg/min CD-NP 
(n=20)
2.5 ng/kg/min CD-NP 
(n=20)
3.75 ng/kg/min CD-NP 
(n=10)
Age, % men 67.1 ± 10.6, 70% 69.4 ± 11, 80% 66 ± 16.8, 70% 71.6 ± 13.8, 80%
Baseline SBP ± SD 133 ± 17 142 ± 20 133 ± 11 137 ± 18
Baseline Cr (mg/dL) ± SD 1.32 ± 0.4 1.46 ± 0.7 1.38 ± 0.4 1.32 ± 0.4
Mean maximum SBP change, mmHg 
± SD
-21 ± 21 -24 ±12 -27±12 -34 ± 20
Change in Cr at end of infusion, mg/
dL ± SD
0.05 ± 0.26 -0.01 ± 0.28 -0.06 ± 0.20 0.10 ± 0.33
Change in cystatin-C at end of infusion, 
mg/dL ± SD
0.07 ± 0.12 
(n=14)
-0.05 ± 0.24 0.0 ± 0.15 0.02 ± 0.27
